Cadrenal Therapeutics, Inc. Common Stock
- Open
- 2.97
- Day high
- 3.24
- Day low
- 2.95
- Prev close
- 3.34
- Volume
- 347K
- Mkt cap
- $9M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.0
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$366K over the last 3 months (0 open-market buys, 21 sales)
- 🏛Institutions reducing (13F)
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a Healthcare company listed on NASDAQ. The stock is down 71% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 21 sales (SEC Form 4).
Cadrenal Therapeutics, Inc. Common Stock (CVKD) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CVKD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-1.51 | $-1.04 | +31.1% | — | — |
| Mar 31, 2026 | $-1.17 | $-1.41 | -20.5% | — | — |
| May 8, 2025 | $-1.64 | $-2.09 | -27.4% | — | — |
| Mar 13, 2025 | $-1.71 | $-2.74 | -60.2% | $2134 | — |
| Nov 7, 2024 | $-1.83 | $-2.18 | -19.1% | — | — |
| May 9, 2024 | $-1.05 | $-1.50 | -42.9% | — | — |
| Mar 11, 2024 | $-1.35 | $-0.75 | +44.4% | $2768 | — |
| Nov 9, 2023 | $-1.05 | $-1.05 | +0.0% | — | — |
| Aug 10, 2023 | — | $-1.35 | — | — | — |
| Jun 30, 2022 | — | $-0.04 | — | — | — |
| Mar 31, 2022 | — | $-0.02 | — | — | — |
CVKD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 26, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 9,029 | $3.05 |
| Jun 26, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 2,127 | $3.00 |
| Jun 24, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 9,167 | $3.55 |
| Jun 24, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 2,277 | $3.20 |
| Jun 18, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 3,613 | $3.18 |
| Jun 18, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 513 | $3.16 |
| Jun 15, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 1,462 | $4.12 |
| Jun 15, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 3,666 | $3.58 |
| Jun 15, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 12,996 | $3.94 |
| Jun 10, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 5,893 | $4.38 |
| Jun 10, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 12,992 | $4.06 |
| Jun 10, 2026 | Pham Quang Xdirector, 10 percent owner, officer: Chairman, CEO and Interim CFO | Sell | 3,500 | $4.21 |
| Jun 5, 2026 | Pham Quang Xdirector, 10 percent owner, officer: CEO and Chairman | Sell | 2,323 | $4.26 |
| Jun 5, 2026 | Pham Quang Xdirector, 10 percent owner, officer: CEO and Chairman | Sell | 2,064 | $4.42 |
| Jun 5, 2026 | Pham Quang Xdirector, 10 percent owner, officer: CEO and Chairman | Sell | 3,898 | $4.41 |
Source: CVKD SEC Form 4 filings, latest Jun 26, 2026. For informational purposes only — not investment advice.
See the full CVKD insider & 13F page →Cadrenal Therapeutics, Inc. Common Stock company profile
Overview
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Ponte Vedra, Florida. The company went public in January 2023 and focuses exclusively on developing a single therapeutic candidate called Tecarfarin, designed to address a critical unmet medical need in patients with end-stage kidney disease who also suffer from atrial fibrillation.
Business
Cadrenal Therapeutics operates in the specialized biotechnology sector, specifically developing treatments for patients with end-stage renal disease (ESRD) combined with atrial fibrillation. This represents a particularly challenging medical condition where patients face dual health crises: their kidneys have failed to the point where they require dialysis or transplantation, and they simultaneously experience irregular heart rhythms that significantly increase their risk of stroke. The company's sole focus is Tecarfarin, a novel anticoagulant therapy that has received orphan drug designation from the FDA. Anticoagulants, commonly known as blood thinners, are medications that prevent blood clots from forming. In patients with atrial fibrillation, the irregular heartbeat can cause blood to pool in the heart chambers, forming clots that can travel to the brain and cause strokes. However, existing anticoagulants like warfarin are problematic for kidney disease patients because these drugs are processed through the kidneys, making dosing extremely difficult and potentially dangerous. Tecarfarin is designed to be a safer alternative because it is metabolized primarily by the liver rather than the kidneys, potentially allowing for more predictable dosing in ESRD patients. The drug is intended for the prevention of systemic thromboembolism of cardiac origin - essentially preventing heart-generated blood clots from traveling throughout the body and causing strokes or other serious complications. This represents a single-product company with 100% of its development efforts concentrated on this one therapeutic candidate.
Revenue model
As a pre-revenue clinical-stage biotechnology company, Cadrenal Therapeutics does not currently generate any revenue from product sales. The company operates on a typical biotech development model where it raises capital through equity financing to fund clinical trials and regulatory activities, with the goal of eventually commercializing Tecarfarin or licensing it to larger pharmaceutical companies. The company's future revenue model would likely involve direct product sales to hospitals, dialysis centers, and specialty pharmacies that serve ESRD patients. Given the orphan drug designation, Tecarfarin would command premium pricing due to the limited patient population and lack of suitable alternatives. The target market consists of the estimated 37,000 ESRD patients in the United States who also have atrial fibrillation, representing a highly specialized but underserved patient population. Several factors could significantly impact the company's future profitability. Positive clinical trial results demonstrating superior safety and efficacy compared to existing treatments would dramatically increase the drug's commercial potential and pricing power. Conversely, any safety concerns or failed trials would essentially eliminate the company's value proposition. Regulatory approval timelines and requirements from the FDA represent another critical factor, as delays could exhaust the company's cash runway. Competition from larger pharmaceutical companies developing alternative treatments for this patient population could also pressure future pricing and market share, though the orphan drug designation provides some protection through market exclusivity periods.
Competitive moat
Cadrenal Therapeutics possesses a relatively narrow competitive moat centered primarily around its orphan drug designation and the specialized nature of its target patient population. The orphan drug status provides seven years of market exclusivity upon approval, protecting against generic competition during this period. Additionally, the company benefits from the significant unmet medical need in ESRD patients with atrial fibrillation, where existing anticoagulants are either contraindicated or require extremely careful monitoring. However, this moat is not particularly strong or durable. The company's competitive advantage relies entirely on a single drug candidate that has not yet completed clinical trials or received regulatory approval. Large pharmaceutical companies with substantially greater resources could develop competing therapies targeting the same patient population. The relatively small market size, while providing some protection from competition, also limits the commercial opportunity and makes the company vulnerable to any competitive threats that do emerge. The most significant competitive risks come from established pharmaceutical giants like Bristol Myers Squibb, Pfizer, or Johnson & Johnson, who have the resources to develop alternative anticoagulants specifically for kidney disease patients. Additionally, advances in kidney transplantation techniques or dialysis technologies could potentially reduce the target patient population over time. The company's single-product focus, while allowing for concentrated expertise, also creates substantial binary risk where the success or failure of Tecarfarin determines the entire company's fate.
Risks & safety
The margin of safety for Cadrenal Therapeutics is moderate but declining, reflecting typical early-stage biotech risks: • Cash position: $7.3 million in cash and short-term investments as of Q1 2025, down from $10.0 million at year-end 2024 • Burn rate: Quarterly cash burn of approximately $4.6 million in Q1 2025, suggesting less than two quarters of runway at current spending levels • Debt: Essentially debt-free with debt-to-equity ratio of 0.0 • Liquidity: Strong current ratio of 4.3x indicating good short-term liquidity coverage • Solvency risk: High near-term risk due to rapid cash depletion and no revenue generation • Valuation: Trading at 2.4x book value and negative enterprise value relative to EBITDA due to cash position exceeding market cap • Binary risk: Success entirely dependent on Tecarfarin clinical trial outcomes and regulatory approval
Recent development
Based on the available financial data, Cadrenal Therapeutics has been primarily focused on advancing Tecarfarin through clinical development since its incorporation in 2022. The company has maintained its singular focus on developing this orphan drug for ESRD patients with atrial fibrillation, with no indication of pipeline diversification or strategic pivots. The company's cash burn has accelerated significantly, increasing from approximately $1.5-2.2 million per quarter in 2024 to $4.6 million in Q1 2025, suggesting intensified clinical trial activities or expanded development programs. This increased spending likely reflects progression into more expensive later-stage clinical trials, which typically require larger patient populations and more comprehensive data collection. The company has maintained a lean operational structure with minimal debt and focused exclusively on its core Tecarfarin program. There have been no apparent strategic partnerships, licensing deals, or business development activities based on the financial statements, indicating the company continues to pursue independent development of its lead candidate.
CVKD company profile · for informational purposes only — not investment advice.
Track CVKD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free